Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))

Wei Tien Tai; Ann Lii Cheng; Chung Wai Shiau; Hsiang Po Huang; Jui Wen Huang; Pei Jer Chen; Kuen Feng Chen

doi:10.1016/j.jhep.2016.12.007

Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))

Wei Tien Tai, Ann Lii Cheng, Chung Wai Shiau, Hsiang Po Huang, Jui Wen Huang, Pei Jer Chen^*, Kuen Feng Chen

^*Corresponding author for this work

Institute of Biopharmaceutical Sciences

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

After careful examination of the raw data included in this manuscript, we found that the Western blots of the internal control, actin, in Fig. 3B and C were the same as the Fig. 2D. We have corrected this error in the revised Fig. 3 below. In addition, the expression level of SOCS-1 and SOCS-3 in Fig. 4E should be under sorafenib 5 μM and 10 μM treatments, rather than sorafenib and SC-1 treatment. The corrected version of Fig. 4 is also included below. The authors would like to apologise for these errors and for any inconvenience this may have caused.

Original language	English
Pages (from-to)	666-668
Number of pages	3
Journal	Journal of Hepatology
Volume	66
Issue number	3
DOIs	https://doi.org/10.1016/j.jhep.2016.12.007
State	Published - 1 Mar 2017

Access to Document

10.1016/j.jhep.2016.12.007

Fingerprint

Dive into the research topics of 'Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))'. Together they form a unique fingerprint.

Cite this

Tai, W. T., Cheng, A. L., Shiau, C. W., Huang, H. P., Huang, J. W., Chen, P. J., & Chen, K. F. (2017). Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)). Journal of Hepatology, 66(3), 666-668. https://doi.org/10.1016/j.jhep.2016.12.007

Tai, Wei Tien ; Cheng, Ann Lii ; Shiau, Chung Wai et al. / Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)). In: Journal of Hepatology. 2017 ; Vol. 66, No. 3. pp. 666-668.

@article{443dc745cc424f77859fe9f84a2c79da,

title = "Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))",

abstract = "After careful examination of the raw data included in this manuscript, we found that the Western blots of the internal control, actin, in Fig. 3B and C were the same as the Fig. 2D. We have corrected this error in the revised Fig. 3 below. In addition, the expression level of SOCS-1 and SOCS-3 in Fig. 4E should be under sorafenib 5 μM and 10 μM treatments, rather than sorafenib and SC-1 treatment. The corrected version of Fig. 4 is also included below. The authors would like to apologise for these errors and for any inconvenience this may have caused.",

author = "Tai, {Wei Tien} and Cheng, {Ann Lii} and Shiau, {Chung Wai} and Huang, {Hsiang Po} and Huang, {Jui Wen} and Chen, {Pei Jer} and Chen, {Kuen Feng}",

note = "Publisher Copyright: {\textcopyright} 2016",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.jhep.2016.12.007",

language = "English",

volume = "66",

pages = "666--668",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "3",

}

Tai, WT, Cheng, AL, Shiau, CW, Huang, HP, Huang, JW, Chen, PJ & Chen, KF 2017, 'Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))', Journal of Hepatology, vol. 66, no. 3, pp. 666-668. https://doi.org/10.1016/j.jhep.2016.12.007

Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)). / Tai, Wei Tien; Cheng, Ann Lii; Shiau, Chung Wai et al.
In: Journal of Hepatology, Vol. 66, No. 3, 01.03.2017, p. 666-668.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))

AU - Tai, Wei Tien

AU - Cheng, Ann Lii

AU - Shiau, Chung Wai

AU - Huang, Hsiang Po

AU - Huang, Jui Wen

AU - Chen, Pei Jer

AU - Chen, Kuen Feng

PY - 2017/3/1

Y1 - 2017/3/1

N2 - After careful examination of the raw data included in this manuscript, we found that the Western blots of the internal control, actin, in Fig. 3B and C were the same as the Fig. 2D. We have corrected this error in the revised Fig. 3 below. In addition, the expression level of SOCS-1 and SOCS-3 in Fig. 4E should be under sorafenib 5 μM and 10 μM treatments, rather than sorafenib and SC-1 treatment. The corrected version of Fig. 4 is also included below. The authors would like to apologise for these errors and for any inconvenience this may have caused.

AB - After careful examination of the raw data included in this manuscript, we found that the Western blots of the internal control, actin, in Fig. 3B and C were the same as the Fig. 2D. We have corrected this error in the revised Fig. 3 below. In addition, the expression level of SOCS-1 and SOCS-3 in Fig. 4E should be under sorafenib 5 μM and 10 μM treatments, rather than sorafenib and SC-1 treatment. The corrected version of Fig. 4 is also included below. The authors would like to apologise for these errors and for any inconvenience this may have caused.

UR - http://www.scopus.com/inward/record.url?scp=85008613402&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2016.12.007

DO - 10.1016/j.jhep.2016.12.007

M3 - Comment/debate

C2 - 28069352

AN - SCOPUS:85008613402

SN - 0168-8278

VL - 66

SP - 666

EP - 668

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 3

ER -

Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ et al. Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)). Journal of Hepatology. 2017 Mar 1;66(3):666-668. doi: 10.1016/j.jhep.2016.12.007

Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this